The Biologics Price Competition and Innovation Act (BPCIA) became law in March of 2010 and since, the potential of biosimilar competition in the US has been a topic of interest to many parties within the health care industry. State and Federal government look to biosimilar competition as an opportunity to reduce health care expenditure, especially […]
written on 31.03.2014
Interchangeability: The Game Changer
